| Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 6596 | 2019 |
| Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ... The lancet Diabetes & endocrinology 7 (8), 606-617, 2019 | 749 | 2019 |
| Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction: subanalysis from the DECLARE-TIMI 58 trial RHM Furtado, MP Bonaca, I Raz, TA Zelniker, O Mosenzon, A Cahn, ... Circulation 139 (22), 2516-2527, 2019 | 389 | 2019 |
| Variation in outcome in studies of out-of-hospital cardiac arrest: a review of studies conforming to the Utstein guidelines M Fredriksson, J Herlitz, G Nichol The American journal of emergency medicine 21 (4), 276-281, 2003 | 177 | 2003 |
| Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE–TIMI 58 study A Cahn, O Mosenzon, SD Wiviott, A Rozenberg, I Yanuv, EL Goodrich, ... Diabetes care 43 (2), 468-475, 2020 | 130 | 2020 |
| Very high survival among patients defibrillated at an early stage after in-hospital ventricular fibrillation on wards with and without monitoring facilities J Herlitz, S Aune, A Bång, M Fredriksson, AB Thorén, L Ekström, ... Resuscitation 66 (2), 159-166, 2005 | 130 | 2005 |
| CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research D Kotecha, FW Asselbergs, S Achenbach, SD Anker, D Atar, C Baigent, ... The Lancet Digital Health 4 (10), e757-e764, 2022 | 96 | 2022 |
| Cardiac arrest outside and inside hospital in a community: mechanisms behind the differences in outcome and outcome in relation to time of arrest M Fredriksson, S Aune, A Bång, AB Thorén, J Lindqvist, T Karlsson, ... American heart journal 159 (5), 749-756, 2010 | 91 | 2010 |
| The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58 O Mosenzon, SD Wiviott, HJL Heerspink, JP Dwyer, A Cahn, EL Goodrich, ... Diabetes Care 44 (8), 1805-1815, 2021 | 90 | 2021 |
| In-hospital cardiac arrest—an Utstein style report of seven years experience from the Sahlgrenska University Hospital M Fredriksson, S Aune, AB Thorén, J Herlitz Resuscitation 68 (3), 351-358, 2006 | 90 | 2006 |
| Nineteen years’ experience of out-of-hospital cardiac arrest in Gothenburg—reported in Utstein style M Fredriksson, J Herlitz, J Engdahl Resuscitation 58 (1), 37-47, 2003 | 77 | 2003 |
| Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58 MP Bonaca, SD Wiviott, TA Zelniker, O Mosenzon, DL Bhatt, LA Leiter, ... Circulation 142 (8), 734-747, 2020 | 67 | 2020 |
| Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial O Mosenzon, I Raz, SD Wiviott, M Schechter, EL Goodrich, I Yanuv, ... Diabetes Care 45 (10), 2350-2359, 2022 | 53 | 2022 |
| Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: post hoc analyses from DECLARE‐TIMI 58 A Cahn, SD Wiviott, O Mosenzon, SA Murphy, EL Goodrich, I Yanuv, ... Diabetes, Obesity and Metabolism 23 (1), 29-38, 2021 | 50 | 2021 |
| Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor … TA Zelniker, DA Morrow, O Mosenzon, EL Goodrich, P Jarolim, ... European journal of heart failure 23 (6), 1026-1036, 2021 | 48 | 2021 |
| Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study A Cahn, I Raz, M Bonaca, O Mosenzon, SA Murphy, I Yanuv, ... Diabetes, Obesity and Metabolism 22 (8), 1357-1368, 2020 | 34 | 2020 |
| Investigators D‐T SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... Dapagliflozin and cardiovascular outcomes in type 2, 347-357, 2019 | 24 | 2019 |
| Implementation of mechanical chest compression in out-of-hospital cardiac arrest in an emergency medical service system C Axelsson, MJ Herrera, M Fredriksson, J Lindqvist, J Herlitz The American journal of emergency medicine 31 (8), 1196-1200, 2013 | 24 | 2013 |
| Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial M Schechter, SD Wiviott, I Raz, EL Goodrich, A Rozenberg, I Yanuv, ... The lancet Diabetes & endocrinology 11 (4), 233-241, 2023 | 17 | 2023 |
| 244-OR: effects of dapagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes: a predefined analysis from the DECLARE-TIMI 58 randomised, placebo … I Raz, SD Wiviott, I Yanuv, A Rozenberg, TA Zelniker, A Cahn, ... Diabetes 68 (Supplement_1), 2019 | 14 | 2019 |
